A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
Okuda H, Shimomura M, Ikeda S, Nakahara M, Miguchi M, Ishizaki Y, Saitoh Y, Toyota K, Sumitani D, Shimizu Y, Takakura Y, Shimizu W, Yoshimitsu M, Kodama S, Fujimori M, Oheda M, Kobayashi H, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO).
Okuda H, et al. Among authors: fujimori m.
Cancer Chemother Pharmacol. 2023 Apr;91(4):317-324. doi: 10.1007/s00280-023-04526-7. Epub 2023 Mar 22.
Cancer Chemother Pharmacol. 2023.
PMID: 36947210
Clinical Trial.